| Rituximab-induced lung disease: A systematic literature review. | |
| | |
MedLine Citation:
|
PMID: 19608586 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The anti-CD20 antibody rituximab has been reported to induce a heterogeneous spectrum of lung disorders. The aim of the present study was to critically review data on the clinical presentations, causality assessments and management strategies of lung diseases possibly related to rituximab. A systematic literature review was performed on English-language reports in PubMed until September 2008. Cases of lung diseases ascribed to rituximab (n = 45) were identified, with three time-to-onset patterns. The most common presentation was acute/subacute hypoxaemic organising pneumonia (n = 37), starting 2 weeks after the last infusion (often around the fourth cycle) and resolving, in most cases, provided glucocorticoid therapy was given early. Acute respiratory distress syndrome occurred in five patients, within a few hours and usually after the first infusion. In the remaining three patients, macronodular organising pneumonia developed insidiously long after rituximab therapy and responded to steroids. Eight patients died. Based on time to onset, symptoms, and responses to discontinuation and rechallenge with rituximab and other drugs, 13 cases were highly compatible and 32 compatible with rituximab-induced lung disease. Knowledge of these presentations of rituximab-induced lung disease should prove helpful for diagnosis and causality assessment purposes. Time-to-onset data, suggesting different pathogenic mechanisms, support closer clinical and perhaps radiological monitoring between infusions, particularly in patients with a history of reversible respiratory symptoms. |
| | |
Authors:
|
H Liot?; F Liot?; B S?roussi; C Mayaud; J Cadranel |
Related Documents
:
|
19850386 - Permanent hearing loss with iopamidol following aortic angiography in a hemodialysis pa... 2196696 - Disulfiram-induced hepatitis. 17567406 - Abuse of dosulepin to induce mania. 11157906 - In vitro activity of new quinolones against clostridium difficile. 20802186 - Human exposures to immobilising agents: results of an online survey. 18442746 - Severe tissue necrosis following intra-arterial injection of endodontic calcium hydroxi... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review Date: 2009-07-16 |
Journal Detail:
|
Title: The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology Volume: 35 ISSN: 1399-3003 ISO Abbreviation: Eur. Respir. J. Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-03-01 Completed Date: 2010-06-24 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8803460 Medline TA: Eur Respir J Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 681-7 Citation Subset: IM |
Affiliation:
|
Centre de comp?tence maladies pulmonaires rares, H?pital -Tenon, Paris, France. huguette.liote@tnn.aphp.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Antibodies, Monoclonal / adverse effects* Biological Factors / adverse effects* Drug Hypersensitivity / physiopathology Female Humans Lung Diseases, Interstitial / chemically induced* Male Middle Aged Respiratory Distress Syndrome, Adult / chemically induced |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Biological Factors; 0/rituximab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Genetic association study of CYP1A1 polymorphisms identifies risk haplotypes in non-small cell lung ...
Next Document: Myeloid related protein 8/14 levels in children with obstructive sleep apnoea.